ROCKET PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $256.51M
- P/E (TTM)
- –
- Dividend yield
- –
About Rocket Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing gene therapies for rare and life-threatening diseases. The company develops treatments using adeno-associated virus and lentiviral vector platforms to target conditions such as Danon disease, Fanconi anemia, pyruvate kinase deficiency, leukocyte adhesion deficiency-I, and cardiomyopathies. Its primary customers and end users include patients afflicted with severe genetic disorders, alongside the physicians, healthcare providers, and clinical institutions that treat these conditions.
The company conducts research, preclinical and clinical testing, and direct manufacturing operations in the United States, while pursuing clinical and commercial relationships abroad, particularly across the European Union. Its operational footprint includes leased office space in New York City as well as facilities in New Jersey. Rocket Pharmaceuticals maintains its principal executive offices and headquarters in Cranbury, New Jersey.
Summary of the business section of Rocket Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ROCKET PHARMACEUTICALS, INC.
- Headquarters
- New York, NY
- Address
- 350 Fifth Avenue, Suite 7530 10118
- Phone
- (646) 440-9100
- Website
- rocketpharma.com
- Employees
- 202, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EISNERAMPER LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- RCKT
- Exchange
- Nasdaq
- IPO date
- Feb 19, 2015
- Shares outstanding
- 110M, Jul 31, 2026
- Public float
- $212.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-4 reverse, Mar 7, 2018; 1-for-4 reverse, Jan 5, 2018
- SEC CIK
- 1281895
- CUSIP
- 77313F106
- ISIN
- US77313F1066
- LEI
- 549300R7VV82YUIN4Y93
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martin Wilson | General Counsel | 598,489 |
| Gaurav Shah | CEO | 1,462,832 |
| Christopher James Stevens | Chief Operating Officer | 505,784 |
| Sarbani Chaudhuri | See Remarks | 262,809 |
| Joseph Manhede | Principal Accounting Officer | 52,576 |
| John Militello | See Remarks | 89,780 |
| Syed Ali-aamir Rizvi | Chief Medical Officer | 407,874 |
| Jonathan David Schwartz | See Remarks | 299,064 |
| Aaron Ondrey | Chief Financial Officer | 128,173 |
| Kinnari Patel | See Remarks | 573,628 |
| Mark Andrew White | See Remarks | 69,140 |
| David P. Southwell | Director | 317,646 |
| Roderick Wong | Director | 18,263,956 |
| Fady Ibraham Malik | Director | 52,862 |
| Mikael Dolsten | Director | 67,082 |
| Peter Fong | Director | 76,195 |
| Carsten Boess | Director | 52,862 |
| Elisabeth Bjork | Director | 50,000 |
| Rtw Investments, Lp | Director | 18,295,124 |
| Gotham Makker | Director | 1,017,412 |
| Pedro P. Granadillo | Director | 54,734 |
| Piratip Pratumsuwan | Director | 30,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Shah | $3.51M | -$327.60K | $3.48M | $18 | $0 |
| FY2024 Mr.Shah | $6.84M | -$1.67M | $3.07M | $64 | $114 |
| FY2023 Mr.Shah | $8.01M | $12.37M | $3.48M | $153 | $115 |
| FY2022 Mr.Shah | $6.55M | $5.19M | $2.71M | $86 | $111 |
| FY2021 Mr.Shah | $7.92M | -$4.33M | $3.60M | $96 | $125 |
| FY2020 Mr.Shah | $6.86M | $21.73M | $1.90M | $241 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 202 full-time employees, of whom 195 were located in the U.S., 6 in Spain, and 1 in Italy.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 2, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Jun 12, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 24, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 1, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 13, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 19, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 21, 2018 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jan 5, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 22, 2017 | Name change | Name changed from INOTEK PHARMACEUTICALS CORP to ROCKET PHARMACEUTICALS, INC. |
| Dec 4, 2017 | Merger vote | Definitive merger proxy statement |
| Feb 19, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 2, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |